PENDING CLAIMS

1.-61. (Previously Canceled).

62. (Previously Presented) A method of inhibiting replication of HIV comprising providing a therapeutically effective amount of alpha hydroxyglycinamide or a pharmaceutically acceptable salt of alpha hydroxyglycinamide to a subject in need thereof.

63. (Previously Presented) The method of Claim 62, wherein a compound of formula (C) is provided.

64. (Previously Presented) The method of Claim 62, wherein a compound of formula (D) is provided.

65. (Previously Presented) The method of Claim 62, further comprising identifying said subject as one in need of an agent that inhibits HIV replication.

66. (Previously Presented) The method of Claim 62, further comprising measuring the presence or absence of HIV or a marker thereof in said subject.

67. (Previously Presented) The method of Claim 62, wherein said subject has an HIV infection.

68. (Previously Presented) The method of Claim 62, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in an oral formulation.

69. (Previously Presented) The method of Claim 62, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a unit dosage form.

70. (Previously Presented) The method of Claim 62, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in an intravenous formulation.

71. (Previously Presented) The method of Claim 62, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a septum sealed vial.

72. (Previously Presented) The method of Claim 62, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a container comprising a certification that said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is a good manufacturing practice (GMP) formulation.

73. (Previously Presented) The method of Claim 62, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a container comprising indicia of approval from a government agency.

74. (Previously Presented) The method of Claim 62, wherein the therapeutically effective amount of said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is 400mg.

75. (Previously Presented) The method of Claim 62, wherein the therapeutically effective amount of said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is 800mg.

76. (Previously Presented) The method of Claim 62, wherein the therapeutically effective amount of said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is 1.2g.

77. (Previously Presented) The method of Claim 74, wherein the therapeutically effective amount of said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided three times a day.

78. (Previously Presented) The method of Claim 75, wherein the therapeutically effective amount of said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided three times a day.

79. (Previously Presented) The method of Claim 76, wherein the therapeutically effective amount of said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided twice a day.

80. (Previously Presented) The method of Claim 63, further comprising identifying said subject as one in need of an agent that inhibits HIV replication.

81. (Previously Presented) The method of Claim 63, further comprising measuring the presence or absence of HIV or a marker thereof in said subject.

82. (Previously Presented) The method of Claim 63, wherein said subject has an HIV infection.

83. (Previously Presented) The method of Claim 63, wherein said compound is provided in an oral formulation.

84. (Previously Presented) The method of Claim 63, wherein said compound is provided in a unit dosage form.

85. (Previously Presented) The method of Claim 63, wherein said compound is provided in an intravenous formulation.

86. (Previously Presented) The method of Claim 63, wherein said compound is provided in a septum sealed vial.

87. (Previously Presented) The method of Claim 63, wherein said compound is provided in a container comprising a certification that said compound is a good manufacturing practice (GMP) formulation.

88. (Previously Presented) The method of Claim 63, wherein said compound is provided in a container comprising indicia of approval from a government agency.

89. (Previously Presented) The method of Claim 63, wherein the therapeutically effective amount of said compound is 400mg.

90. (Previously Presented) The method of Claim 63, wherein the therapeutically effective amount of said compound is 800mg.

91. (Previously Presented) The method of Claim 63, wherein the therapeutically effective amount of said compound is 1.2g.

92. (Previously Presented) The method of Claim 89, wherein the therapeutically effective amount of said compound is provided three times a day.

93. (Previously Presented) The method of Claim 90, wherein the therapeutically effective amount of said compound is provided three times a day.

94. (Previously Presented) The method of Claim 91, wherein the therapeutically effective amount of said compound is provided twice a day.

95. (Previously Presented) The method of Claim 64, further comprising identifying said subject as one in need of an agent that inhibits HIV replication.

96. (Previously Presented) The method of Claim 64, further comprising measuring the presence or absence of HIV or a marker thereof in said subject.

97. (Previously Presented) The method of Claim 64, wherein said subject has an HIV infection.

98. (Previously Presented) The method of Claim 64, wherein said compound is provided in an oral formulation.

99. (Previously Presented) The method of Claim 64, wherein said compound is provided in a unit dosage form.

100. (Previously Presented) The method of Claim 64, wherein said compound is provided in an intravenous formulation.

101. (Previously Presented) The method of Claim 64, wherein said compound is provided in a septum sealed vial.

102. (Previously Presented) The method of Claim 64, wherein said compound is provided in a container comprising a certification that said compound is a good manufacturing practice (GMP) formulation.

103. (Previously Presented) The method of Claim 64, wherein said compound is provided in a container comprising indicia of approval from a government agency.

104. (Previously Presented) The method of Claim 64, wherein the therapeutically effective amount of said compound is 400mg.

105. (Previously Presented) The method of Claim 64, wherein the therapeutically effective amount of said compound is 800mg.

106. (Previously Presented) The method of Claim 64, wherein the therapeutically effective amount of said compound is 1.2g.

107. (Previously Presented) The method of Claim 104, wherein the therapeutically effective amount of said compound is provided three times a day.

108. (Previously Presented) The method of Claim 105, wherein the therapeutically effective amount of said compound is provided three times a day.

109. (Previously Presented) The method of Claim 106, wherein the therapeutically effective amount of said compound is provided twice a day.